Zydus Lifesciences Ltd (ZYDUSLIFE)
₹1,245.50
Mkt cap
₹1.24L Cr
P/E ratio
25.50
P/B
4.63
Div yield
0.08%
ROE
21.20%
ROCE
21.10%
EPS (TTM)
₹48.84
Book value
₹269
52W range
836–1,249
Sector
Healthcare
Price history
Previous close
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
NSE ZYDUSLIFEBSE 532321
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−0.27% from high₹1,246
₹836+49.07% from low₹1,249
Current
₹1,245.50
Prev close
₹1,184.40
Day
+5.16%
Price performance
1D
+5.16%
1W
+10.28%
1M
+3.75%
3M
+11.69%
6M
+36.74%
1Y
+23.44%
YTD
+35.84%
Financials
Revenue, profit & margin
P/E ratio
25.5×
ZYDUSLIFE is 26% below the sector median of 34.4×
ZYDUSLIFE25.5×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,140 | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 | |
| Expenses | 3,634 | 3,223 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 | |
| Operating Profit | 1,505 | 1,146 | 1,102 | 1,630 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 | |
| OPM % | 29% | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% | |
| Other Income | 21 | 53 | 60 | 160 | 63 | 68 | 57 | -139 | 155 | 75 | 26 | -263 | 88 | |
| Interest | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 | |
| Depreciation | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 | |
| Profit before tax | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 | |
| Tax % | 16% | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% | |
| Net Profit | 1,134 | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 | |
| EPS in Rs | 10.74 | 7.91 | 7.80 | 11.75 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.42 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.29% · closed higher next day 29 of last 61
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 9 Feb '24◦ | 17 May '24◦ | 9 Aug '24◦ | 12 Nov '24◦ | 5 Feb '25◦ | 20 May '25◦ | 12 Aug '25 | 6 Nov '25 | 9 Feb '26 | 19 May '26 | 11 Aug '26 |
| Earnings day | +4.67% | +6.41% | +5.00% | −3.88% | +1.47% | +3.19% | +0.72% | +0.01% | −3.60% | +3.97% | +2.80% | +1.18% |
| +1 day | +2.54% | +6.55% | +3.51% | −9.64% | +0.81% | +1.76% | +2.28% | +3.46% | −2.84% | −0.10% | +5.02% | −1.99% |
| +5 days | +5.78% | +12.73% | +0.68% | −8.32% | −0.07% | −3.50% | +4.79% | +2.90% | −2.84% | +2.51% | +8.87% | −7.26% |
| +15 days | +7.10% | +17.54% | +3.30% | −14.37% | +4.77% | −10.28% | +10.81% | +5.90% | −3.55% | +2.11% | +10.82% | −3.09% |
| +30 days | +13.84% | +24.18% | +2.21% | −19.17% | +0.76% | −5.46% | +12.69% | +6.67% | −5.97% | −0.20% | +10.97% | −0.90% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Re 1 Per Share | — | 24 Jul '26 | 24 Jul '26 |
| other Buy Back | — | 29 May '26 | 29 May '26 |
Shareholding
as of Sep 202675.01%Promoter
Promoters75.01%
FIIs7.05%0.16
DIIs11.28%
Public6.66%0.17
Government0.00%
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts84
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTMay 2025TranscriptMar 2025PPTMar 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Change in Management 31 OctAnnouncement under Regulation 30 (LODR)-Newspaper Publication 30 Oct - The newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on October …Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Oct - Zydus Lifesciences Q2 FY27 results on November 4, 2026; earnings call at 3:30 p.m. IST.Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 Oct - Zylidac Bio and Prolific Machines partner to scale biologics platform to GMP production.Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 Oct - Zydus wins USFDA approval for transdermal system; eligible for 180-day exclusivity, U.S. sales $45.7 mn.